Niowave's $75M Radiopharmaceutical Plant: Industry Implications
Decision brief
Answer first · skim in under a minute
Niowave has initiated construction on a $75 million radiopharmaceutical plant in Michigan, marking a significant investment in Actinium-225 production. This development has far-reaching implications for the pharmaceutical industry and investment strategies.
Niowave broke ground on May 21, 2026, on a $75 million radiopharmaceutical plant in Lansing, Michigan, aimed at scaling Actinium-225 (Ac-225) supply for targeted alpha cancer therapies, with operations expected in 2028 and about 70 skilled jobs.
Contents10 sections
Key Takeaways
- Niowave announced a $75 million second Lansing production facility on May 21, 2026, focused on Ac-225.
- The company targets operational start in 2028 and about 70 highly skilled jobs.
- The site will add proprietary superconducting linear accelerators plus processing and quality systems.
- Niowave cited two major Ac-225 supply agreements in the prior four months, including a Novartis deal announced February 11, 2026.
- FDA PET manufacturing guidance and EMA radiopharmaceutical quality guidelines remain core CMC references for isotope-drug sponsors.
What did Niowave announce in Lansing?
According to Niowave's May 21, 2026 company release, the firm broke ground on a new $75 million production facility in Lansing.
The plant is Niowave's second dedicated production site in the city. Construction is led by The Christman Company with Colliers Engineering & Design.
Niowave said the investment strengthens domestic Ac-225 supply for next-generation targeted cancer therapies and will create about 70 highly skilled jobs.
How will the plant expand Ac-225 capacity?
Niowave said the facility will feature multiple proprietary superconducting linear accelerators and new processing and quality systems.
The company framed the build as a response to rising demand for Ac-225, an alpha-emitting isotope used in targeted alpha therapy designs that seek to kill tumor cells while limiting damage to healthy tissue.
Operations are expected to begin in 2028. Until then, sponsors dependent on scalable Ac-225 should treat capacity as a planning constraint, not a solved input.
Why Ac-225 supply shapes radiopharma pipelines
Actinium-225 scarcity has been a practical bottleneck for targeted alpha therapy programs. Manufacturing scale often limits trial enrollment and commercial readiness more than target biology alone.
Niowave said biopharma interest grew rapidly and that it announced two major supply agreements in the four months before the groundbreaking.
On February 11, 2026, Niowave said it entered a global Ac-225 supply agreement with Novartis to support radioligand therapy development.
Teams tracking isotope-dependent assets should map supply contracts against Phase 2/3 start dates and commercial launch assumptions.
What should BD and CMC teams watch?
Business development and chemistry, manufacturing, and controls (CMC) teams need three concurrent workstreams.
First, confirm isotope identity, purity specs, and delivery logistics in supply agreements. Second, align drug product CMC with isotope half-life and cold-chain realities. Third, pressure-test backup suppliers because single-source Ac-225 creates operational risk.
Competitive context also matters for portfolio strategy. Related NovaPharma coverage includes FDA gene therapy guidance for BD teams and Lilly retatrutide Phase 3 competitive implications.
Which regulatory documents guide PET and radiopharmaceutical CMC?
Sponsors should start with primary regulator texts rather than trade commentary.
The FDA CMC guidance for PET drugs covers current good manufacturing practice expectations for positron emission tomography products.
The EMA quality guideline for radiopharmaceuticals sets European expectations for quality documentation.
For clinical activity using Ac-225, teams can monitor open trials via ClinicalTrials.gov Actinium-225 search results.
Implications for Michigan manufacturing and U.S. isotope policy
Niowave said the Lansing campus expansion reinforces Michigan's advanced manufacturing and life sciences base.
From a national supply-chain view, domestic Ac-225 capacity reduces dependence on limited foreign isotope streams for U.S. oncology programs.
That said, groundbreaking is not capacity. Investors and partners should track construction milestones, accelerator installation, and first commercial curie output before revising scarcity assumptions.
For adjacent U.S. regulatory risk monitoring, see FDA Listeria soft-cheese investigation coverage.
How should investors model the 2028 capacity ramp?
Groundbreaking in May 2026 does not equal commercial curies in 2026. Sponsors should model Ac-225 availability on a 2028 start, then add commissioning risk of several quarters.
Niowave's public plan pairs accelerator count with radiochemistry throughput. Investors should ask for disclosed annual curie targets once the site is nearer start-up, and compare those figures with contracted volumes for Novartis and other disclosed partners.
Until audited production data appear, treat Ac-225 scarcity as easing later in the decade rather than solved today. Pipeline models that assume unlimited alpha-emitter supply in 2027 remain aggressive.
Frequently Asked Questions
What did Niowave announce about its Michigan plant?
On May 21, 2026, Niowave said it broke ground on a new $75 million Actinium-225 production facility in Lansing, Michigan, its second dedicated site there, with operations targeted for 2028.
Why does Actinium-225 supply matter for pharma?
Ac-225 is an alpha-emitting isotope used in targeted cancer therapies. Supply constraints have limited clinical and commercial scale, so domestic capacity expansions affect radiopharmaceutical pipelines.
Which partners has Niowave disclosed for Ac-225 supply?
Niowave said it announced two major Ac-225 supply agreements in the four months before the groundbreaking, including a February 2026 global supply agreement with Novartis.
Primary Sources
Regulatory catalyst tracker
Track upcoming PDUFA dates and regulatory milestones for drugs in this story.
Unlock full calendar →Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
